Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|GOG-0275||GOG||A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6183||ECOG-ACRIN||A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1007||SWOG||A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041703||Alliance||Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|E3999||ECOG||A Randomized; Placebo-controlled; Double Blind; Trial of the Administration of the MDR Modulator; Zosuquidar Trihydrochloride (LY335979); During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia; Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts||Adult CIRB - Late Phase Emphasis||Completed|
|EA5163||ECOG-ACRIN||INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCIC-MA.32||NCIC CTG||A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCICOVID||NCI||NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-47||NSABP||A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|